Ascendis Pharma A/S
ASND165.765USD
+1.614+0.98%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
10.05BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ascendis Pharma A/S Unternehmen
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Unternehmensinformationen
Unternehmens-codeASND
Name des UnternehmensAscendis Pharma A/S
IPO-datumJan 28, 2015
Gegründet am2006
CEOMr. Jan Moller Mikkelsen
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJan 28
AddresseTuborg Boulevard 12
StadtHELLERUP
BörseNASDAQ Global Select Consolidated
LandDenmark
Postleitzahl2900
Telefon4570222244
Websitehttps://ascendispharma.dk/
Unternehmens-codeASND
IPO-datumJan 28, 2015
Gegründet am2006
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Umsatzaufteilung
Währung: EURUpdate-Zeit: Sun, Apr 6
Währung: EURUpdate-Zeit: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Nach RegionEUR
Name
Umsatz
Anteil
North America
48.76M
84.31%
Europe
8.15M
14.09%
Asia
924.00K
1.60%
Rest of world
924.00K
1.60%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Aktionäre
Update-Zeit: Sat, Apr 26
Update-Zeit: Sat, Apr 26
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Aktionärsstatistik
Aktionäre
Anteil
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
42.21%
Investment Advisor
39.31%
Hedge Fund
25.01%
Research Firm
2.54%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Family Office
0.44%
Venture Capital
0.38%
Institutionelle Beteiligung
Update-Zeit: Mon, Jan 20
Update-Zeit: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
473
67.43M
111.11%
-2.45M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
2022Q4
426
67.66M
118.40%
-4.66M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
10.11M
16.66%
+402.32K
+4.14%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.53M
9.11%
+394.47K
+7.68%
Dec 31, 2024
Avoro Capital Advisors LLC
5.10M
8.41%
+114.17K
+2.29%
Dec 31, 2024
Artisan Partners Limited Partnership
4.45M
7.33%
+39.31K
+0.89%
Dec 31, 2024
Janus Henderson Investors
4.38M
7.22%
+193.69K
+4.63%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.36M
7.18%
-196.51K
-4.32%
Dec 31, 2024
Capital International Investors
2.86M
4.72%
+753.86K
+35.74%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.73M
4.49%
+960.50K
+54.42%
Dec 31, 2024
T. Rowe Price Associates, Inc.
2.28M
3.76%
+162.08K
+7.64%
Dec 31, 2024
MFS Investment Management
1.86M
3.07%
-415.00
-0.02%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Harbor Health Care ETF
16.1%
Virtus LifeSci Biotech Products ETF
1.93%
BNY Mellon Innovators ETF
1.85%
Tema Cardiovascular and Metabolic ETF
1.43%
American Century Focused Dynamic Growth ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.94%
Invesco Nasdaq Biotechnology ETF
0.9%
JPMorgan Healthcare Leaders ETF
0.66%
iShares Biotechnology ETF
0.61%
Main Thematic Innovation ETF
0.61%
Mehr Anzeigen
Harbor Health Care ETF
Anteil16.1%
Virtus LifeSci Biotech Products ETF
Anteil1.93%
BNY Mellon Innovators ETF
Anteil1.85%
Tema Cardiovascular and Metabolic ETF
Anteil1.43%
American Century Focused Dynamic Growth ETF
Anteil1.43%
ProShares Ultra Nasdaq Biotechnology
Anteil0.94%
Invesco Nasdaq Biotechnology ETF
Anteil0.9%
JPMorgan Healthcare Leaders ETF
Anteil0.66%
iShares Biotechnology ETF
Anteil0.61%
Main Thematic Innovation ETF
Anteil0.61%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten